ACCP Practice Statement: "Over-the-Counter Epinephrine for Asthma Treatment: Too Much Risk for Too Little Benefit"
The Practice Statement highlights ACCP formally joining numerous medical organizations in emphasizing the hazards of over-the-counter (OTC) availability of inhaled epinephrine products for the treatment of asthma .
- The Practice Statement highlights ACCP formally joining numerous medical organizations in emphasizing the hazards of over-the-counter (OTC) availability of inhaled epinephrine products for the treatment of asthma .
- Further, ACCP supports the implementation of pharmacist-centered asthma management programs which allow for the provision of asthma-related medication refills and care strategy related to pharmacotherapy.
- The recommendations made are in the best interest of quality healthcare access and the awareness of inherent dangers of using OTC inhaled epinephrine products for asthma.
- This statement was published to bring awareness of the ramifications of OTC epinephrine use in asthma and encourages patients to consult with a healthcare professional for appropriate asthma pharmacotherapy management.